Molecular Partners is a biopharmaceutical company that focuses on the discovery, development, and commercialization of biopharmaceutical products for the treatment of wet age-related macular degeneration and diabetic macular edema. It also develops ankyrin repeat protein therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments.
Market capitalization (3-Sept-2021)
Closing stock price (3-Sept-2021)
Molecular Partners has 259 Twitter Followers. The number of followers has increased 0.6% month over month and increased 4.4% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Molecular Partners founded?
Molecular Partners was founded in 2004.
Who are Molecular Partners key executives?
Molecular Partners's key executives are Michael Tobias Stumpp, Patrick Amstutz and Andreas Emmenegger.
How many employees does Molecular Partners have?
Molecular Partners has 145 employees.
Who are Molecular Partners competitors?
Competitors of Molecular Partners include Abliva, WuXi AppTec and BioSpecifics Technologies.
Where is Molecular Partners headquarters?
Molecular Partners headquarters is located at 14 Wagistrasse, Zürich-Schlieren.
Where are Molecular Partners offices?
Molecular Partners has offices in Zürich-Schlieren and Cambridge.
How many offices does Molecular Partners have?
Molecular Partners has 2 offices.
Receive alerts for 300+ data fields across thousands of companies